



National Comprehensive
Cancer Network®

Tumor Boards

A Multidisciplinary Approach to Individualized Patient Care



Molecularly Guided Treatment of Adult Gliomas

LIVE WEBINAR



Friday, August 7, 2026
2:00 – 3:00 PM EDT

REGISTER

<https://education.nccn.org/node/98654>

AVAILABLE CREDIT

1.0 AAPA Category 1 CME credit
1.0 ACPE contact hour
1.0 AMA PRA Category 1 Credit™
1.0 ANCC contact hour
1.0 CCM clock hour
1.0 Participation

OVERVIEW

With the use of genetic and molecular testing, gliomas can be differentiated more accurately in terms of prognosis and, in some instances, response to different therapies. It's crucial to understand the emerging role of genetic and molecular testing in the management of adult gliomas. The timing and choice of treatment including observation, systemic therapy, and RT are critical in patients with oligodendroglioma or astrocytoma.

TARGET AUDIENCE


This program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician associates, pharmacists, and other health care professionals who manage patients with cancer.

FEATURED FACULTY FROM NCCN MEMBER INSTITUTION

O'Neal Comprehensive Cancer Center at UAB



John Fiveash, MD



Burt Nabors, MD

LEARNING OBJECTIVES

- Recognize differences between *IDH*-mutant astrocytoma and oligodendroglioma (1p/19q-codeleted and *IDH*-mutant) and review the role of molecular/genetic characterization of adult gliomas.
- Describe results from recent clinical trials for patients with newly diagnosed oligodendroglioma or astrocytoma.
- Discuss timing and choice of appropriate adjuvant treatment options for patients with newly diagnosed oligodendroglioma or astrocytoma.